Vaniprevir

Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing. In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.
Wikipedia contributors, "Vaniprevir", Wikipedia, revision 1330639451, retrieved 20 November 2026, source, CC BY-SA 4.0.